In the crowded field of surgical ablation, where heat and cold have long been the dominant tools, a different kind of energy is carving out a niche. Galvanize Therapeutics is betting that brief, high-voltage electrical pulses can destroy cancerous and diseased tissue with a precision that spares the surrounding anatomy, a technique known as pulsed electric field (PEF) ablation. For patients facing complex lung tumors or the unrelenting cough of chronic bronchitis, the promise is a procedure that targets only what it must, potentially reducing collateral damage and recovery time. It is a fundamentally different mechanism, and one that has now attracted over $330 million in venture capital to move from clinical promise to standard of care [PRNewswire, Nov 2026].
The physics of a gentler cut
The company's wedge is nonthermal tissue destruction. Its principal commercial system, Aliya, delivers microsecond bursts of high-voltage electricity directly to soft tissue. Unlike thermal ablation, which cooks cells with heat and can damage nearby blood vessels and nerves, the electrical pulses are thought to create nanoscale pores in cell membranes, triggering a form of regulated cell death without significant heat generation [Citybiz, Nov 2026]. This physical approach is the core of Galvanize's two-platform strategy.
- Aliya for oncology. Cleared by the FDA for the surgical ablation of soft tissue, the Aliya system is used in procedures for lung and other cancers. By November 2026, more than 4,000 commercial procedures had been performed using the platform [Finsmes, Nov 2026]. A next-generation generator, the Aliya EX, received FDA clearance in 2026 and began commercial use that August [Dealroom, Nov 2026].
- RheOx for airways. The company's second platform applies PEF energy to the airway walls and is being developed for patients with chronic bronchitis, a debilitating symptom of COPD. The RheOx Bronchial Rheoplasty System is currently being evaluated in the RheSolve pivotal study, a randomized, sham-controlled trial that had enrolled its 270th patient [LinkedIn, 2026].
The regulatory pathway reflects this bifurcation. Aliya holds multiple FDA 510(k) clearances as a surgical tool, allowing for commercial sale [Galvanize Therapeutics]. RheOx, aiming to treat a chronic disease, requires the more rigorous PMA pathway, hence the ongoing pivotal trial.
A merger, a new CEO, and a $130 million vote of confidence
Galvanize was formed in 2022 through the merger of Gala Therapeutics and Galaxy Medical, combining PEF programs for chronic lung disease and oncology [Galvanize Therapeutics]. Leadership solidified in 2025 with the appointment of medtech veteran Doug Godshall as CEO and chairman [Citybiz, Nov 2026]. The company's founding physicians, Seth Harrison, MD, and Jonathan Waldstreicher, MD, who co-invented the core technologies, remain involved [Galvanize Therapeutics].
Financing has followed in substantial increments, underscoring the capital intensity of medical device development and clinical trials. A $100 million Series B coincided with the merger in 2022, followed by a $100 million Series C in September 2025 led by Sofinnova Partners [StartupsRaised, Nov 2026]. The most recent round, a $130 million Series D in November 2026, was led by HealthQuest Capital, which placed its founder and managing partner, Garheng Kong, on Galvanize's board [Finsmes, Nov 2026].
2022 Series B | 100 | M USD
2025 Series C | 100 | M USD
2026 Series D | 130 | M USD
Building evidence in the real world
Beyond controlled trials, Galvanize is amassing real-world data. The company's PROPEL registry, an observational study tracking the use of its PEF technology, had enrolled more than 300 patients across up to 25 U.S. sites by late 2026 [Citybiz, Nov 2026]. For Aliya, early clinical data is promising. The AFFINITY study, investigating Aliya for Stage IV lung cancer, reported positive six-month results showing the system was safe and provided high local tumor control [Interventional News, 2026]. Another study is evaluating the safety of using Aliya prior to planned surgical resection of lung lesions [MedPath Trial].
This evidence-building is critical not just for clinical adoption but for commercial traction in hospital systems. The over 4,000 procedures performed represent a growing base of surgeon experience, a key metric for a capital equipment sale that requires training and changes to surgical workflow.
The competitive and clinical landscape
Pulsed electric field ablation is not without established players, particularly in cardiac electrophysiology. Galvanize's focus on soft tissue oncology and pulmonary disease sets it apart, but it operates in well-funded therapeutic areas with entrenched standards of care. The primary competitive pressure is not a direct PEF rival but the inertia of existing technologies,radiofrequency ablation, cryoablation, and surgical resection,that surgeons know intimately. Convincing oncologists and pulmonologists to adopt a new energy modality requires demonstrating not just non-inferiority but a clear clinical benefit, such as preserving lung function or reducing complications.
The company's most plausible answer is specialization and data. By focusing Aliya on complex thoracic oncology cases and RheOx on a high-symptom-burden COPD population, it can build deep expertise. The ongoing RheSolve trial, if successful, would provide the level-one evidence needed to change treatment guidelines for chronic bronchitis, a condition with few effective interventions.
What standard of care looks like today
For a patient with an inoperable lung tumor today, the options often involve thermal ablation, which carries a risk of damaging the delicate lung parenchyma and nearby structures. The procedure can be painful, and recovery may be protracted. For the millions with chronic bronchitis, standard care is largely pharmacological,inhaled corticosteroids, bronchodilators, and mucolytics,which often provide incomplete relief from the relentless cough and mucus production. There are few, if any, durable device-based interventions. This is the clinical void into which Galvanize is deploying its capital and technology: offering interventionalists a tool that aims to be more precise for the cancer patient and offering the COPD patient a potential new avenue for lasting symptom relief. The next twelve months will be defined by the progress of the RheSolve trial and the continued commercial rollout of the Aliya EX generator, as the company works to translate its substantial funding into equally substantial patient impact.
Sources
- [PRNewswire, Nov 2026] Galvanize Therapeutics, Inc. Announces Oversubscribed $130 Million Series D Financing | https://www.prnewswire.com/news/galvanize-therapeutics,-inc./
- [Citybiz, Nov 2026] T. Rowe Price-Backed Galvanize Therapeutics Secures $130M Led by HealthQuest | https://www.citybiz.co/article/934423/t-rowe-price-backed-galvanize-therapeutics-secures-130m-led-by-healthquest/
- [Finsmes, Nov 2026] Galvanize Therapeutics Raises $130M in Series D Financing | https://www.finsmes.com/2026/11/galvanize-therapeutics-raises-130m-in-series-d-financing.html
- [Galvanize Therapeutics] About Galvanize Therapeutics | https://galvanizetx.com/about/
- [StartupsRaised, Nov 2026] Galvanize Therapeutics Raises Series D Plus | https://www.startupsraised.com/news/galvanize-therapeutics-raises-series-d-plus
- [Dealroom, Nov 2026] Galvanize raises $130M Series D for pulsed field expansion | https://dealroom.co/news/173060/galvanize-raises-130m-series-d-for-pulsed-field-expansion
- [LinkedIn, 2026] RheOx Bronchial Rheoplasty System update | https://www.linkedin.com/in/seth-harrison-0707b0b0/
- [Interventional News, 2026] AFFINITY clinical trial demonstrates safety and high local control for Aliya PEF | https://www.interventionalnews.com/
- [MedPath Trial] Study evaluating safety of Aliya PEF prior to surgical resection | https://www.medpathtrial.com/
- [ClinicalTrials.gov] PROPEL Registry details | https://www.clinicaltrials.gov/